BC Innovations | Jan 23, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Lymphoma Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 (KIR3DL1; CD158E1); KIR3DL2 (CD158K); KIR3DL3 (CD158Z); CD20 In vitro and mouse studies suggest combining...
BC Innovations | Feb 3, 2011
Distillery Therapeutics

Indication: Endocrine disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Endocrine disease Diabetes Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 (KIR3DL1; KIR; CD158E1) Studies in mice suggest that downregulating...
BC Innovations | Jul 15, 2010
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Multiple myeloma (MM) Killer cell immunoglobulin-like receptor three domains short cytoplasmic tail 1 (KIR3DS1; CD158E2); killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1...
Items per page:
1 - 3 of 3